Literature DB >> 28848170

Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.

Stella Welter1, Caroline Lücke, Alexandra Philomena Lam, Christina Custal, Sebastian Moeller, Peter Sörös, Christiane M Thiel, Alexandra Philipsen, Helge H O Müller.   

Abstract

BACKGROUND: Consumption of natural cannabis (NC) and synthetic cannabinoids (SCs) has been associated with psychotic disorders. We compared the prevalence of use, consumer profiles, and psychosis-inducing potential of NC and SCs in a specific high-risk population.
METHODS: This prospective pilot study included 332 patients (18-64 years, mean 36.83, SD 13.33). Patients' sociodemographics and medical histories as well as illicit substance use and psychiatric symptom histories were collected using a drug consumption survey that assessed the use of new psychoactive substances and the Psychotic Symptoms Interview.
RESULTS: In total, 7.2% of all patients, 10.6% of psychotic patients, and 4.5% of nonpsychotic patients reported SC consumption. Compared with SCs, NC was consumed much more frequently by its users (mean 222.73, SD 498.27). NC and SC use induced persistent psychosis. Psychotic symptoms were first experienced by patients with a history of NC or SC use during intoxication and persisted after cessation (>1 year) of drug use. Positive and negative symptoms tended to be more severe in SC and NC users, respectively.
CONCLUSIONS: NC and SCs may cause different symptom clusters. These relationships should be further evaluated.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Cannabinoid consumption; Psychosis; Synthetic cannabinoid consumption

Mesh:

Substances:

Year:  2017        PMID: 28848170     DOI: 10.1159/000479554

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  5 in total

Review 1.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

2.  Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users.

Authors:  Koby Cohen; Shiri Rosenzweig; Paola Rosca; Albert Pinhasov; Abraham Weizman; Aviv Weinstein
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

3.  Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study.

Authors:  Melissa Hobbs; Rashmi Patel; Paul D Morrison; Nicola Kalk; James M Stone
Journal:  J Psychopharmacol       Date:  2020-02-28       Impact factor: 4.153

Review 4.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

Review 5.  Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.

Authors:  Edward Chesney; Dominic Oliver; Philip McGuire
Journal:  Psychopharmacology (Berl)       Date:  2021-07-13       Impact factor: 4.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.